omnifalo.blogg.se

Adverse events were subdivided as follows: Delays in treatment, dose reductions, hospitalizations and chemotherapy regime changes.

Data was collected concerning the chemotherapy regimen, adverse events associated with chemotherapy, disease progression and recurrence and 5-year survival. The exclusion criteria included chemotherapy for palliation and patients living outside of Alberta. A retrospective chart review of patients diagnosed with stage III or IV colorectal cancer between 20 was performed. The aim of the current study was to develop a urine metabolomics-based biomarker panel to predict adverse events and response to chemotherapy in patients with colorectal cancer. The ability to predict a patient's response to chemotherapy may be of great value for clinicians and patients when planning cancer treatment. Colorectal cancer is the third leading cause of cancer-associated mortality in the western world.